We are live on ! Find out more
CRL icon

Charles River Laboratories

561 hedge funds and large institutions have $13.6B invested in Charles River Laboratories in 2021 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 199 increasing their positions, 211 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 49

17% more capital invested

Capital invested by funds: $11.7B → $13.6B (+$1.96B)

13% more funds holding in top 10

Funds holding in top 10: 1517 (+2)

4% more funds holding

Funds holding: 538561 (+23)

0.57% more ownership

Funds ownership: 94.16%94.73% (+0.57%)

6% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 211

21% less call options, than puts

Call options by funds: $52.6M | Put options by funds: $66.8M

Holders
561
Holders Change
+23
Holders Change %
+4.28%
% of All Funds
9.85%
Holding in Top 10
17
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+13.33%
% of All Funds
0.3%
New
76
Increased
199
Reduced
211
Closed
49
Calls
$52.6M
Puts
$66.8M
Net Calls
-$14.1M
Net Calls Change
-$22M
Name Holding Trade Value Shares
Change
Change in
Stake
UFF
426
USA Financial Formulas
Michigan
$270K +$259K +933 New
BOPW
427
Brandywine Oak Private Wealth
Pennsylvania
$267K -$12.2K -44 -5%
FWIA
428
Fort Washington Investment Advisors
Ohio
$261K
RHBC
429
R.H. Bluestein & Co
Michigan
$261K
PSUF
430
People's United Financial
Connecticut
$260K +$9.17K +33 +4%
ESCM
431
Echo Street Capital Management
New York
$259K -$72.3K -260 -23%
CG
432
Caprock Group
Idaho
$259K +$11.7K +42 +5%
HIM
433
Hotaling Investment Management
Pennsylvania
$252K -$14.5K -52 -6%
Lido Advisors
434
Lido Advisors
California
$245K +$6.95K +25 +3%
Wealthfront Advisers
435
Wealthfront Advisers
California
$245K +$235K +847 New
GT
436
Glenmede Trust
Pennsylvania
$240K -$29.7K -107 -11%
OIA
437
Optimum Investment Advisors
Illinois
$239K
OSAM
438
O'Shaughnessy Asset Management
Connecticut
$233K -$2.78K -10 -1%
SFSIG
439
San Francisco Sentry Investment Group
California
$232K
GWM
440
Geneos Wealth Management
Colorado
$232K +$18.1K +65 +10%
PGFC
441
Peapack-Gladstone Financial Corp
New Jersey
$226K -$8.62K -31 -4%
UCFA
442
United Capital Financial Advisors
Texas
$225K +$215K +775 New
GTCM
443
Gyon Technologies Capital Management
New Jersey
$221K +$212K +762 New
V
444
Veritable
Delaware
$219K +$210K +754 New
Mercer Global Advisors
445
Mercer Global Advisors
Colorado
$219K +$210K +756 New
RCAG
446
Rehmann Capital Advisory Group
Michigan
$217K -$38.6K -139 -16%
NPP
447
New Potomac Partners
Maryland
$217K +$208K +750 New
CA
448
Cetera Advisors
Colorado
$212K +$204K +733 New
FC
449
FORA Capital
Florida
$208K -$191K -687 -49%
GT
450
Greenleaf Trust
Michigan
$208K +$200K +719 New

CRL Hedge Fund Activity: Q1 2021 in Review

561 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2021, worth a combined $13.6B — up 17% from $11.7B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new CRL positions and 49 closed out — a net gain of 27 holders — while 199 added to existing stakes and 211 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $239M. The largest seller was Fidelity International, cutting an estimated $83.1M.

  • 561 institutional investors held Charles River Laboratories (CRL) as of Q1 2021, up from 538 in Q4 2020.
  • Funds reported $13.6B of Charles River Laboratories stock for Q1 2021, up 17% quarter-over-quarter.
  • 76 funds opened new Charles River Laboratories positions in Q1 2021 and 49 closed out, a net change of +27 holders.
  • The largest Charles River Laboratories buyer in Q1 2021 was William Blair Investment Management, an estimated $239M added.
  • The largest Charles River Laboratories seller in Q1 2021 was Fidelity International, an estimated $83.1M sold.

Based on aggregated 13F filings for Q1 2021.